Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 301–400 of 1,018
Vardeny, O., Claggett, B., Anand, I., Rossignol, P., Desai, A. S., Zannad, F., Pitt, B., & Solomon, S. D. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001104 · Cited by 209
Self-citationWeir, R. A. P., McMurray, J. J. V., & Velazquez, E. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.005 · Cited by 211
Bousquet, E., Beydoun, T., Zhao, M., Hassan, L., Offret, O., & Behar-Cohen, F. (2013) · Retina · doi:10.1097/iae.0b013e318297a07a · Cited by 212
Freemantle, N., Marston, L., Walters, K., Wood, J., Reynolds, M. R., & Petersen, I. (2013) · BMJ · doi:10.1136/bmj.f6409 · Cited by 211
State of the Art: Clinical Applications of Cardiac T1 Mapping
Schelbert, E. B., & Messroghli, D. R. (2016) · Radiology · doi:10.1148/radiol.2016141802 · Cited by 206
McKelvie, R. S., Moe, G. W., Ezekowitz, J. A., Heckman, G. A., Costigan, J., Ducharme, A., Estrella-Holder, E., Giannetti, N., Grzeslo, A., Harkness, K., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.10.007 · Cited by 208
Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., & Plouin, P.-F. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.157271 · Cited by 202
Implantable Defibrillators and Sudden Cardiac Death
Josephson, M., & Wellens, H. J. J. (2004) · Circulation · doi:10.1161/01.cir.0000129322.97266.f3 · Cited by 206
Merrill, M., Sweitzer, N. K., Lindenfeld, J., & Kao, D. P. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.01.003 · Cited by 201
Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J.-J., Dhakal, S., Franconi, F., Gouni-Berthold, I., Heiman, M. L., Kautzky-Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 192
Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
Berl, T., & Henrich, W. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730805 · Cited by 201
The Nongenomic Actions of Aldosterone
Funder, J. W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0004 · Cited by 200
Adrenal Corticosteroid Biosynthesis, Metabolism, and Action
Arlt, W., & Stewart, P. M. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.002 · Cited by 195
Associations of serum potassium levels with mortality in chronic heart failure patients
Aldahl, M., Jensen, A.-S. C., Davidsen, L., Eriksen, M. A., Møller Hansen, S., Nielsen, B. J., Krogager, M. L., Køber, L., Torp-Pedersen, C., & Søgaard, P. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx460 · Cited by 196
The Sympathetic Nervous System and Heart Failure
Zhang, D. Y., & Anderson, A. S. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.010 · Cited by 194
Kuster, G. M., Kotlyar, E., Rude, M. K., Siwik, D. A., Liao, R., Colucci, W. S., & Sam, F. (2005) · Circulation · doi:10.1161/01.cir.0000153800.09920.40 · Cited by 195
Keidar, S., Gamliel-Lazarovich, A., Kaplan, M., Pavlotzky, E., Hamoud, S., Hayek, T., Karry, R., & Abassi, Z. (2005) · Circulation Research · doi:10.1161/01.res.0000187500.24964.7a · Cited by 193
Hsich, E. M., & Piña, I. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.066 · Cited by 198
Anand, I. S., Carson, P., Galle, E., Song, R., Boehmer, J., Ghali, J. K., Jaski, B., Lindenfeld, J., O'Connor, C., Steinberg, J. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.793273 · Cited by 192
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiss, U., Pook, E., Schäfer, S., Rafestin-Oblin, M.-E., & Kolkhof, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.131342 · Cited by 191
Wu, W., Muchir, A., Shan, J., Bonne, G., & Worman, H. J. (2011) · Circulation · doi:10.1161/circulationaha.110.970673 · Cited by 190
Sex and Gender Differences in Heart Failure
Regitz-Zagrosek, V. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0004 · Cited by 174
Faris, R. F., Flather, M., Purcell, H., Poole-Wilson, P. A., & Coats, A. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003838.pub4 · Cited by 195
Raine, R., Fitzpatrick, R., Barratt, H., Bevan, G., Black, N., Boaden, R., Bower, P., Campbell, M., Denis, J.-L., Devers, K., et al. (2016) · Health Services and Delivery Research · doi:10.3310/hsdr04160 · Cited by 186
Jneid, H., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.032 · Cited by 188
Montalescot, G., Pitt, B., Lopez de Sa, E., Hamm, C. W., Flather, M., Verheugt, F., Shi, H., Turgonyi, E., Orri, M., Vincent, J., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu164 · Cited by 187
Self-citationThe evolution of aldosterone antagonists
Garthwaite, S. M., & McMahon, E. G. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.005 · Cited by 189
Beygui, F., Collet, J.-P., Benoliel, J.-J., Vignolles, N., Dumaine, R., Barthélémy, O., & Montalescot, G. (2006) · Circulation · doi:10.1161/circulationaha.106.634626 · Cited by 190
Lenzen, M. J., Boersma, E., Scholte op Reimer, W. J. M., Balk, A. H. M. M., Komajda, M., Swedberg, K., Follath, F., Jimenez-Navarro, M., Simoons, M. L., & Cleland, J. G. F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi499 · Cited by 193
Sica, D. A. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2345-1 · Cited by 192
Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity
Nagata, D., Takahashi, M., Sawai, K., Tagami, T., Usui, T., Shimatsu, A., Hirata, Y., & Naruse, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000226054.53527.bb · Cited by 187
Raebel, M. A. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 188
Mineralocorticoid receptors in vascular function and disease
McCurley, A., & Jaffe, I. Z. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.014 · Cited by 178
Kosiborod, M., Soto, G. E., Jones, P. G., Krumholz, H. M., Weintraub, W. S., Deedwania, P., & Spertus, J. A. (2007) · Circulation · doi:10.1161/circulationaha.106.670901 · Cited by 190
Savoye, C., Equine, O., Tricot, O., Nugue, O., Segrestin, B., Sautière, K., Elkohen, M., Pretorian, E. M., Taghipour, K., Philias, A., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.011 · Cited by 183
Cardiovascular effects of relaxin: from basic science to clinical therapy
Du, X.-J., Bathgate, R. A. D., Samuel, C. S., Dart, A. M., & Summers, R. J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.198 · Cited by 188
Ahmed, A., Zannad, F., Love, T. E., Tallaj, J., Gheorghiade, M., Ekundayo, O. J., & Pitt, B. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm091 · Cited by 184
Self-citationCardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage
Fiebeler, A., Nussberger, J., Shagdarsuren, E., Rong, S., Hilfenhaus, G., Al-Saadi, N., Dechend, R., Wellner, M., Meiners, S., Maser-Gluth, C., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.521625 · Cited by 182
The renin-angiotensin-aldosterone system and its therapeutic targets
Mirabito Colafella, K. M., Bovée, D. M., & Danser, A. H. J. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.05.020 · Cited by 175
Shah, S. J., Heitner, J. F., Sweitzer, N. K., Anand, I. S., Kim, H.-Y., Harty, B., Boineau, R., Clausell, N., Desai, A. S., Diaz, R., et al. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.972794 · Cited by 181
Self-citationSmith, S. C., Jr. (2019) · PubMed · doi:10.17615/vf9y-es17 · Cited by 184
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.185752 · Cited by 187
Anker, S. D., Kosiborod, M., Zannad, F., Piña, I. L., McCullough, P. A., Filippatos, G., van der Meer, P., Ponikowski, P., Rasmussen, H. S., Lavin, P. T., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.300 · Cited by 183
Self-citationNeural modulation of cardiac arrhythmias and sudden cardiac death
Zipes, D. P., & Rubart, M. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2005.09.021 · Cited by 183
Zannad, F., Gattis Stough, W., Rossignol, P., Bauersachs, J., McMurray, J. J. V., Swedberg, K., Struthers, A. D., Voors, A. A., Ruilope, L. M., Bakris, G. L., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs257 · Cited by 178
Self-citationConnell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0030 · Cited by 182
Rosano, G. M. C., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., Drexel, H., Patak, A., Torp-Pedersen, C., Kjeldsen, K. P., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv161 · Cited by 175
Cytochrome P450 enzymes: Central players in cardiovascular health and disease
Elbekai, R. H., & El-Kadi, A. O. S. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.011 · Cited by 181
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Hypertension · doi:10.1161/hyp.0000000000000018 · Cited by 176
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Kintscher, U., Bakris, G. L., & Kolkhof, P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15747 · Cited by 173
Leitlinien zur Therapie der chronischen Herzinsuffizienz
Hoppe, U. C., Böhm, M., Dietz, R., Hanrath, P., Kroemer, H. K., Osterspey, A., Schmaltz, A. A., & Erdmann, E. (2005) · Zeitschrift für Kardiologie · doi:10.1007/s00392-005-0268-4 · Cited by 169
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Self-citationVascular Actions of Aldosterone
Briet, M., & Schiffrin, E. L. (2013) · Journal of Vascular Research · doi:10.1159/000345243 · Cited by 174
Grossmann, C., Benesic, A., Krug, A. W., Freudinger, R., Mildenberger, S., Gassner, B., & Gekle, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0469 · Cited by 178
The association between congestive heart failure and chronic renal disease
Silverberg, D., Wexler, D., Blum, M., Schwartz, D., & Iaina, A. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200403000-00004 · Cited by 177
Collins, P., Rosano, G., Casey, C., Daly, C., Gambacciani, M., Hadji, P., Kaaja, R., Mikkola, T., Palacios, S., Preston, R., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm296 · Cited by 177
Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019) · Circulation Research · doi:10.1161/circresaha.118.313568 · Cited by 176
Mehta, P. A., & Dubrey, S. W. (2009) · QJM · doi:10.1093/qjmed/hcn147 · Cited by 173
Primary Aldosteronism: Practical Approach to Diagnosis and Management
Byrd, J. B., Turcu, A. F., & Auchus, R. J. (2018) · Circulation · doi:10.1161/circulationaha.118.033597 · Cited by 169
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
Diuretics: A Review and Update
Roush, G. C., Kaur, R., & Ernst, M. E. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413497257 · Cited by 164
Cardiorenal Syndrome in Acute Decompensated Heart Failure
Sarraf, M., Masoumi, A., & Schrier, R. W. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03150509 · Cited by 171
Jneid, H., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000032 · Cited by 168
Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
Aldigier, J. C., Kanjanbuch, T., Ma, L.-J., Brown, N. J., & Fogo, A. B. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090804 · Cited by 171
Tomaschitz, A., Pilz, S., Ritz, E., Meinitzer, A., Boehm, B. O., & Marz, W. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq019 · Cited by 171
Bhagat, A. A., Greene, S. J., Vaduganathan, M., Fonarow, G. C., & Butler, J. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.06.011 · Cited by 169
The Role of Aldosterone in Obesity-Related Hypertension
Kawarazaki, W., & Fujita, T. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw003 · Cited by 165
WRITING COMMITTEE MEMBERS, Krumholz, H. M., Anderson, J. L., Bachelder, B. L., Fesmire, F. M., Fihn, S. D., Foody, J. M., Ho, P. M., Kosiborod, M. N., Masoudi, F. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.191099 · Cited by 170
Martínez-Martínez, E., Calvier, L., Fernández-Celis, A., Rousseau, E., Jurado-López, R., Rossoni, L. V., Jaisser, F., Zannad, F., Rossignol, P., Cachofeiro, V., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05876 · Cited by 163
Self-citationSavoia, C., Touyz, R. M., Amiri, F., & Schiffrin, E. L. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.103267 · Cited by 169
Packer, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 160
The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure
Cat, A. N. D., Griol‐Charhbili, V., Loufrani, L., Labat, C., Benjamin, L., Farman, N., Lacolley, P., Henrion, D., & Jaisser, F. (2010) · The FASEB Journal · doi:10.1096/fj.09-147926 · Cited by 161
Ezekowitz, J. A., & McAlister, F. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn543 · Cited by 166
Aldosterone antagonists for preventing the progression of chronic kidney disease
Navaneethan, S. D., Nigwekar, S. U., & Strippoli, G. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004 · Cited by 166
Prognostic Value of Estimated Plasma Volume in Heart Failure
Duarte, K., Monnez, J.-M., Albuisson, E., Pitt, B., Zannad, F., & Rossignol, P. (2015) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.06.014 · Cited by 164
Self-citationPaterna, S., Fasullo, S., Cannizzaro, S., Vitrano, G., Terrazzino, G., Maringhini, G., Ganci, F., Scalzo, S., Di Pasquale, P., Parrinello, G., et al. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31820f10ad · Cited by 163
Krum, H., & Abraham, W. T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60236-1 · Cited by 159
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Segall, L., Nistor, I., & Covic, A. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 158
Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction
Goldberg, L. R., & Jessup, M. (2006) · Circulation · doi:10.1161/circulationaha.105.600437 · Cited by 164
Odermatt, A., & Kratschmar, D. V. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.020 · Cited by 159
Mineralocorticoid Receptor–Mediated Vascular Insulin Resistance
Bender, S. B., McGraw, A. P., Jaffe, I. Z., & Sowers, J. R. (2013) · Diabetes · doi:10.2337/db12-0905 · Cited by 158
Schäfer, N., Lohmann, C., Winnik, S., van Tits, L. J., Miranda, M. X., Vergopoulos, A., Ruschitzka, F., Nussberger, J., Berger, S., Lüscher, T. F., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht095 · Cited by 158
Cardiomyopathy, familial dilated
Taylor, M. R., Carniel, E., & Mestroni, L. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-27 · Cited by 159
Acid–base and electrolyte abnormalities in heart failure: pathophysiology and implications
Urso, C., Brucculeri, S., & Caimi, G. (2015) · Heart Failure Reviews · doi:10.1007/s10741-015-9482-y · Cited by 178
Faris, R. F., Flather, M., Purcell, H., Poole-Wilson, P. A., & Coats, A. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003838.pub3 · Cited by 156
RetractedSalt, aldosterone, and insulin resistance: impact on the cardiovascular system
Lastra, G., Dhuper, S., Johnson, M. S., & Sowers, J. R. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.123 · Cited by 169
Perioperative Management of Chronic Heart Failure
Groban, L., & Butterworth, J. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000226099.60493.d9 · Cited by 162
Rossignol, P., Cleland, J. G. F., Bhandari, S., Tala, S., Gustafsson, F., Fay, R., Lamiral, Z., Dobre, D., Pitt, B., & Zannad, F. (2012) · Circulation · doi:10.1161/circulationaha.111.028282 · Cited by 158
Self-citationEplerenone: Cardiovascular Protection
Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000071081.35693.9a · Cited by 158
Salivary Cortisol Is Related to Atherosclerosis of Carotid Arteries
Dekker, M. J. H. J., Koper, J. W., van Aken, M. O., Pols, H. A. P., Hofman, A., de Jong, F. H., Kirschbaum, C., Witteman, J. C. M., Lamberts, S. W. J., & Tiemeier, H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0496 · Cited by 154
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Kolkhof, P., & Borden, S. A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.025 · Cited by 171
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias
Iravanian, S., & Dudley, S. C. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.02.025 · Cited by 161
Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?
WEIR, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.019 · Cited by 169
Hanslik, G., Wallaschofski, H., Dietz, A., Riester, A., Reincke, M., Allolio, B., Lang, K., Quack, I., Rump, L. C., Willenberg, H. S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0450 · Cited by 155
Role of Rac1–mineralocorticoid-receptor signalling in renal and cardiac disease
Nagase, M., & Fujita, T. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.282 · Cited by 160
Delgado, V., Mollema, S. A., Ypenburg, C., Tops, L. F., van der Wall, E. E., Schalij, M. J., & Bax, J. J. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.08.010 · Cited by 153
Butrous, H., & Hummel, S. L. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.05.005 · Cited by 144
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.